Literature DB >> 19565091

Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling.

Hancheng Cai1, John Fissekis, Peter S Conti.   

Abstract

Copper-64 shows promise as both a suitable PET imaging and therapeutic radionuclide due to its nuclear characteristics. Stable attachment of radioactive (64)Cu(2+) to targeted imaging probes requires the use of a bifunctional chelator. Sarcophagine (Sar) ligands coordinate the metal ion (64)Cu(2+) within the multiple macrocyclic rings comprising the cage structure, yielding extraordinarily stable complexes that are inert to dissociation of the metal ion in vivo. Several (64)Cu labelled RGD derivatives have been applied in imaging of the alpha(nu)beta(3) integrin receptor expression during tumour angiogenesis. In order to design and develop novel molecular imaging probes containing RGD and Sar ligands, we designed a novel versatile Sar cage-like bifunctional chelator named AmBaSar, synthesized using a conventional synthetic strategy. Conjugation with the cyclic peptide RGD, and subsequent labelling with (64)Cu, provided a new PET probe (64)Cu-AmBaSar-RGD for imaging the alpha(nu)beta(3) integrin receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565091     DOI: 10.1039/b902210d

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  17 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  Designing protein-based biomaterials for medical applications.

Authors:  Jennifer E Gagner; Wookhyun Kim; Elliot L Chaikof
Journal:  Acta Biomater       Date:  2013-10-09       Impact factor: 8.947

3.  Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals.

Authors:  Shuanglong Liu; Zibo Li; Li-Peng Yap; Chiun-Wei Huang; Ryan Park; Peter S Conti
Journal:  Chemistry       Date:  2011-08-04       Impact factor: 5.236

4.  Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.

Authors:  Sibaprasad Bhattacharyya; Manish Dixit
Journal:  Dalton Trans       Date:  2011-05-03       Impact factor: 4.390

5.  Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer.

Authors:  Chiun-Wei Huang; Zibo Li; Hancheng Cai; Kai Chen; Tony Shahinian; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

6.  Efficient construction of PET/fluorescence probe based on sarcophagine cage: an opportunity to integrate diagnosis with treatment.

Authors:  Shuanglong Liu; Dan Li; Chiun-Wei Huang; Li-Peng Yap; Ryan Park; Hong Shan; Zibo Li; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2012-12       Impact factor: 3.488

Review 7.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

8.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

9.  Phosphonate Pendant Armed Propylene Cross-Bridged Cyclam: Synthesis and Evaluation as a Chelator for Cu-64.

Authors:  Nikunj Bhatt; Nisarg Soni; Yeong Su Ha; Woonghee Lee; Darpan N Pandya; Swarbhanu Sarkar; Jung Young Kim; Hochun Lee; Sun Hee Kim; Gwang Il An; Jeongsoo Yoo
Journal:  ACS Med Chem Lett       Date:  2015-10-20       Impact factor: 4.345

10.  Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs.

Authors:  Kye-Il Joo; Liang Xiao; Shuanglong Liu; Yarong Liu; Chi-Lin Lee; Peter S Conti; Michael K Wong; Zibo Li; Pin Wang
Journal:  Biomaterials       Date:  2013-01-30       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.